Clairity Appoints Jeffrey R. Luber as CEO
Company Poised to Revolutionize Breast Cancer Screening through AI-based Risk Prediction
Clairity, Inc., a pioneer in AI-driven predictive tools for breast cancer, has officially announced the appointment of Jeffrey R. Luber, JD, MBA, as President, Chief Executive Officer, and Director. With extensive experience in oncology, genetic sequencing, and digital health, Luber is set to guide Clairity through its upcoming market launch and global expansion.
Luber expressed his enthusiasm for joining the company at such a pivotal time. He stated, "Too many patients receive a cancer diagnosis when it's too late to make a real difference. Clairity's mission focuses on developing products that transform current screening practices, enabling us to identify high-risk patients earlier to improve care and prognosis. Our AI-powered risk assessments will equip clinicians and patients with timely, data-driven information to act sooner than what mammography alone has allowed."
The mission of Clairity is to enhance breast cancer screening accessibility and effectiveness for all, irrespective of race, ethnicity, or geographical location. The company’s flagship product, Allix5, leverages AI to analyze screening mammograms, identifying individuals at heightened risk of developing breast cancer. By utilizing a vast array of diverse imaging data and clinical outcomes, Clairity aims to offer innovative approaches for risk prediction.
Dr. Connie Lehman, MD, PhD, co-founder of Clairity and a notable authority in the field of breast imaging AI, highlighted the vital role of machine learning in improving mammography processes. "Our research initiatives and collaborative efforts have laid the foundation for a new era in breast cancer screening," Dr. Lehman commented. "Jeff's wealth of experience in leading innovative life sciences companies will be instrumental as we embark on this next exciting phase of growth for Clairity. Together, we will work to deploy AI prognostics for millions of women at risk."
In relation to plans for a global launch, Kevin Lalande, Founding Managing Director of Santé, an early-stage healthcare investment firm and a lead investor in Clairity, noted that Luber's appointment demonstrates their commitment to transforming breast cancer care. Luber's extensive career encompasses guiding various healthcare organizations through all stages of development, from research to market launch. His prior position as CEO of binx health saw the company reach first-in-market status in a significant category for infectious disease testing, significantly impacting underserved areas with innovative digital health solutions. Luber is currently the Chairman of binx.
His past roles include CEO of Good Start Genetics, which was sold to Invitae in 2017, and President & CEO of Exact Sciences, where he was pivotal in establishing DNA-based testing for colorectal cancer as the standard approach, recognized by notable organizations such as the American Cancer Society under his leadership.
About Clairity, Inc.
Clairity, Inc. stands at the forefront of utilizing AI to improve breast cancer screening and risk assessment. Through advanced imaging data and predictive algorithms, Clairity's platform aims to deliver personalized information to healthcare providers and patients alike. The company is dedicated to making precision medicine available to everyone.
About Santé Ventures
Santé Ventures, founded in 2006, is a specialized investment firm focused on early-stage healthcare and life sciences, managing approximately $800 million in capital. The firm actively invests in innovative medical technologies, biotechnologies, and digital healthcare services. Recent successes include partnerships with prominent companies in the healthcare sector. Santé maintains offices in both Austin and Boston.
Media Inquiries
For inquiries, contact Ryan Walker from R.J. Walker & Co.
860.930.3611
Frequently Asked Questions
1. What is the significance of Jeffrey Luber's appointment as CEO?
Jeffrey Luber's leadership is expected to spearhead Clairity's global expansion and innovation in breast cancer screening technology.
2. How does Clairity's technology work?
Clairity's technology analyzes mammograms using AI to identify patients at increased risk of developing breast cancer through predictive algorithms.
3. What is the mission of Clairity?
Clairity aims to enhance breast cancer screening effectiveness for everyone, focusing on early risk identification.
4. What experience does Jeffrey Luber bring to Clairity?
Luber has extensive experience in healthcare leadership, specifically in guiding companies through various stages of growth and market entry.
5. How is AI impacting breast cancer screening?
AI is revolutionizing breast cancer screening by offering personalized, data-driven assessments that enhance early detection and treatment planning.
